PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents
Phase 3
Completed
- Conditions
- Growth Hormone Deficiency
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2007-07-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT00156143
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients
Terminated
- Conditions
- Familial Adenomatous Polyposis (FAP)
- Interventions
- Other: Routine Medical Care
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2010-03-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 68
- Registration Number
- NCT00151476
- Locations
- 🇪🇸
Pfizer Investigational Site, Barcelona, Spain
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
Phase 4
Completed
- Conditions
- Acromegaly
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2008-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00151437
- Locations
- 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada
A Study of the Safety and Efficacy of Tofimilast in Adult Asthmatics
Phase 2
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 112
- Registration Number
- NCT00150397
- Locations
- 🇮🇳
Pfizer Investigational Site, Noida, Uttar Pradesh, India
12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation
Phase 2
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2007-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT00150228
- Locations
- 🇺🇸
Pfizer Investigational Site, Madison, Wisconsin, United States
A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation
Phase 2
Completed
- Conditions
- Smoking Cessation
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 625
- Registration Number
- NCT00150241
- Locations
- 🇺🇸
Pfizer Investigational Site, Morgantown, West Virginia, United States
Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 147
- Registration Number
- NCT00150345
- Locations
- 🇩🇪
Pfizer Investigational Site, Wuerzburg, Germany
Linezolid for the Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus in Japan
Phase 3
Completed
- Conditions
- Infections, Nosocomial
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00150332
- Locations
- 🇯🇵
Pfizer Investigational Site, Okayama, Japan
A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension
Phase 3
Completed
- Conditions
- Glaucoma, Open-AngleOcular Hypertension
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2008-11-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 976
- Registration Number
- NCT00150267
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Demonstrate Exubera Works As Well As Avandia When Added To Sulfonylurea + Metformin In Controlling Glucose
Phase 3
Completed
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2008-10-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 626
- Registration Number
- NCT00150410
- Locations
- 🇲🇽
Pfizer Investigational Site, Mexico Df, Mexico
© Copyright 2025. All Rights Reserved by MedPath